Skip to main content
Amneal Pharmaceuticals, Inc. logo

Amneal Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · AMRX ISIN · US03168L1052 LEI · 549300VV176ZO5WQHZ61 US Manufacturing
Open in API
Filings indexed 633 across all filing types
Latest filing 2026-04-22 M&A Activity
Country US United States of America
Listing US AMRX

About Amneal Pharmaceuticals, Inc.

https://amneal.com/

Amneal Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company that develops, manufactures, and distributes a broad portfolio of essential medicines. The company maintains a robust generics business, with over 280 products, and a growing specialty division focused on branded pharmaceuticals. Key therapeutic areas include oncology, with innovative cancer and supportive care therapies, and central nervous system disorders such as Parkinson's disease. Amneal specializes in developing complex medicines, including first-to-file and first-to-market opportunities, to increase affordable access for patients. Additionally, its AvKARE segment distributes pharmaceuticals to U.S. federal government, retail, and institutional markets.

Recent filings

Filing Released Lang Actions
8-K - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)
M&A Activity Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes an announcement of a material definitive agreement (an acquisition agreement), preliminary first quarter financial results, a conference call announcement, and an investor presentation availability. It does not contain full financial statements or detailed financial analysis itself but references a press release and investor presentation. The document is about a merger/acquisition transaction and related disclosures, but it is not a merger proxy statement or tender offer filing. The presence of a conference call and investor presentation announcement also supports this. Given the nature of the Form 8-K and the content, the best fitting category is "M&A Activity (TAR)" because it announces and describes the acquisition agreement and related transaction details. The document is substantial in length and content, not just a brief announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Confidence is high due to clear identification of the acquisition agreement and related transaction disclosures in a Form 8-K.
2026-04-22 English
SCHEDULE 13D/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)
Major Shareholding Notification
2026-03-26 English
SCHEDULE 13G/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)
Major Shareholding Notification
2026-03-26 English
DEFA14A - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)
Proxy Solicitation & Information Statement Classification · 100% confidence The document is identified as a 'DEFA14A' filing, which stands for Definitive Additional Proxy Soliciting Materials. It is a Schedule 14A proxy statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. The text explicitly mentions 'Definitive Proxy Statement' and 'Definitive Additional Materials' and is related to proxy solicitation. This type of document is used to provide shareholders with information and request votes for meetings, fitting the Proxy Solicitation & Information Statement category. The document length is short (1173 characters), but it is not merely an announcement of a report; it is the proxy solicitation material itself. Therefore, the correct classification is PSI.
2026-03-25 English
DEF 14A - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)
Proxy Solicitation & Information Statement
2026-03-25 English
4 - AMNEAL PHARMACEUTICALS, INC. (0001723128) (Filer)
Director's Dealing
2026-03-03 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.